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Abstract
Background: The objective of this study was to investigate the association between KIR genes and the
immunopathogenesis of leprosy.
Methods: The types of KIR and HLA genes were evaluated by PCR-SSOP-Luminex in 408 patients with leprosy and
413 healthy individuals. Statistical analysis was performed using the Chi-square or Fisher’s exact test and stepwise
multivariate analysis.
Results: There was a higher frequency of activating KIR genes (KIR2DS1, 2DS2 and 3DS1) together with their HLA
ligands in the tuberculoid (TT) group as compared to the lepromatous leprosy (LL) group. KIR2DL2/2DL2-C1 was
more frequent in the patient, TT and LL groups than in the control group. Borderline patients presented a higher
frequency of inhibitory pairs when compared to the control group, and a higher frequency of activating pairs as
compared to the LL group. Multivariate analysis confirmed the associations and demonstrated that being a female
is a protective factor against the development of the disease per se and the more severe clinical form.
Conclusions: This study showed that activating and inhibitory KIR genes may influence the development of
leprosy – in particular, activating genes may protect against the more aggressive form of the disease – thereby
demonstrating the role of NK cells in the immunopathology of the disease.
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Background
Leprosy or Hansen’s disease is a chronic, slowly develop-
ing infectious disease caused by Mycobacterium leprae,
which global prevalence has been decreasing over recent
years due to effective multiple drug therapy. However,
the detection of new cases remains constant at approxi-
mately 250,000 per year, with pockets of high endemicity
existing in countries such as Brazil, Angola, Africa,
India, Nepal, and the United Republic of Tanzania [1].
In Brazil, leprosy has been diagnosed in all regions
of the country, with the Northern and Mid-Western
regions being hyperendemic and the Northeastern re-
gion having high endemicity [2].
The most widely used classification model for the dis-
ease is that of Ridley-Jopling, which divides the disease
into five polar and interpolar forms: Tuberculoid (TT),
Borderline-Tuberculoid (BT), Borderline-Borderline (BB),
Borderline-lepromatous leprosy (BL) and Lepromatous
leprosy (LL) [3]. Initially, the disease is of indeterminate
form, which may regress spontaneously or evolve into one
of these stages. The clinical manifestations of the disease
depend on factors such as the ability of the bacilli to prolif-
erate and the immune response presented by the host [4].
Over the years, research has been aimed at better un-
derstanding the genetics of susceptibility to the different
clinical forms of leprosy. The clinical and pathological
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spectrum of leprosy and the epidemiological, geographical,
and ethnic heterogeneity might be explained by genetic
differences in the host’s resistance. While some loci affect
the intrinsic susceptibility to leprosy itself, others modify
the clinical form of the disease [5]. Among the candidate
genes for an individual’s susceptibility or resistance to lep-
rosy are the KIR (Killer Immunoglobulin-Like Receptor)
genes. These genes span over approximately 150 Kb of
the LCR (Leukocyte Receptor Complex) region of chro-
mosome 19q13.4, which encodes KIRs, members of a
group of regulatory molecules present on the surface of
NK (Natural Killer) cells [6].
The KIRs are the main functional regulators of NK
cells; the activity of these effector cells is determined by
the balance between their activation and inhibition that
occurs as a result of the binding of KIRs with HLA class
I molecules present in all nucleated cells [7]. Most KIRs
bind to HLA-C molecules; the KIR2DL2 and KIR2DL3
inhibitory receptors interact with HLA-C of Group 1,
while KIR2DL1 recognizes HLA-C of Group 2. In the
absence of these inhibitory receptors, NK cells can be
activated by activating receptors, such as KIR2DS1 and
KIR2DS2 [8]. The genotype may predispose a subject to
certain interactions that vary from activation to inhi-
bition depending on the individual’s KIR/HLA profile [9].
To date, only one study has reported an association
between KIR genes and their HLA ligands with leprosy
phenotypes, using a population sample of 165 patients
from south Brazil [10]. Thus, the aim of this study was
to investigate the association between KIR genes and
their HLA ligands in the development of leprosy and its
clinical forms in patients from the hyperendemic region
of Rondonópolis, Mato Grosso, Mid-Western Brazil,
ultimately aiming to better understand the immuno-
pathogenic mechanisms of M. leprae.
Methods
Population and epidemiological data collection
This study was approved by the Research Ethics Com-
mittee of the Instituto Lauro de Souza Lima Bauru, São
Paulo, Brazil, and funded by the Conselho Nacional de
Desenvolvimento Científico e Tecnológico (CNPq). All
participants signed an informed consent form agreeing
to participate in the study. Data for epidemiological
characterization were collected in government health-
care clinics by applying a questionnaire and by revisiting
medical records and notification registration forms of
patients treated between 2006 and 2009.
This case–control study was conducted using a popula-
tion sample from Rondonópolis (Mid-Western State of
Mato Grosso, Brazil: latitude 16°28′15″ South and longi-
tude 54°38′08″ West), consisting of 408 patients with
leprosy (250 men and 158 women) with a median age of
41 years treated in government healthcare clinics of the
municipality of Rondonópolis. The patients were classified
into distinct groups according to the Ridley-Jopling cri-
teria [3]: LL (5.14%), borderline (BL 15.4%; BB 25.8%; BT
39.4%) and TT (14.7%), with 25 patients (6.12%) present-
ing the indeterminate form of the disease. The control
group consisted of healthy individuals 413 (249 men and
164 women) with a median age of 42 years. The following
criteria were used while forming the control group: no
family and/or personal history with leprosy and no history
of chronic infections, inflammation, or autoimmune dis-
eases. The control group was matched to the case group
according to epidemiological characteristics such as ethni-
city, gender, age and geographical region.
DNA extraction
After collecting 5 mL of peripheral venous blood in
EDTA anticoagulant, the extraction and purification of
DNA were performed by selective precipitation using
the technique described by John et al. [11].
Typing of the KIR genes and HLA class I alleles
Typing of the KIR genes and HLA class I alleles (HLA-
A, −B, −C) was performed by PCR-SSOP (Polymerase
Chain Reaction-Sequence Specific Oligonucleotide Probes)
using the SSO LabType® kit (One Lambda, San Diego, CA,
USA) after evaluating the purity and adjusting the con-
centration of the DNA (20 ng). The amplified product was
hybridized with microspheres bound to probes specific for
the KIR gene and HLA class I alleles. The resulting pro-
ducts were analysed using a LUMINEX® flow cytometer
and the results were compared by HLA Fusion™ (One
Lambda, San Diego, CA, USA).
Statistical analysis
The frequencies of KIR genes and HLA class I alleles were
obtained by direct counting and by comparing these fre-
quencies between patients and controls using the Chi-
square test with Yates correction or Fisher’s exact test
using a 2 × 2 contingency table with a 95% confidence
interval (95% CI). The risk of developing leprosy and its
clinical forms was calculated by determining the OR (odds
ratio) for P-values < 0.05 according to Wolf [12], using the
statistics program OpenEpi v. 2.3.1 (http://www.openepi.
com/OE2.3/Menu/OpenEpiMenu.htm). P values were cor-
rected by the Bonferroni inequality method, by multiplying
them by the number of KIR genes analysed.
Subsequently, multivariate logistic regression analysis
was performed using stepwise method of data analysis,
using age, gender and ethnicity as covariates, employing
IBM® SPSS® 20.0 Statistics software (SPSS, IBM Inc.,
Chicago, IL, USA) with the level of significance set at 5%
(P-value ≤ 0.05).
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Results
The characteristics of the study population with respect to
age, gender and ethnic group are shown in Table 1. Both
the mean and median ages were similar among all groups
(Total Patients, LL, Borderline, TT and Control), demon-
strating a good match between cases and controls.
There was a predominance of men in the total patients
(61.2%), LL (80.9%), Borderline (64.2%) and Control
groups (60.2%), while the TT group was composed pre-
dominantly of females (58.3%). There was a predominance
of Afro-Brazilians followed by Caucasians and Blacks in
all groups, with similar proportions of ethnicity in each
group.
The distribution of KIR gene frequencies is shown in
Table 2. There were significant differences in the allelic
distributions of the KIR2DL1 gene when comparing the
Total Patient and Control Groups (87.0% vs. 96.2%,
P-value < 0.001, Pc < 0.014, OR = 0.3, 95% CI = 0.2-0.5)
and Borderline and Control Groups (86.0% vs. 96.2%,
P-value < 0.001, Pc < 0.014, OR = 0.2, 95% CI: 0.1-0.5).
There was also a trend (P-value = 0.07) for positive as-
sociation between the KIR3DS1 activating gene and the
TT when compared to the LL form of the disease (43.3%
vs. 19.0%).
Data on the distribution of KIR genes with their corre-
lated HLA class I ligands are shown in Table 3. For the
KIR2DS2-C1 activating receptor, the frequency was lower
for the Control Group (20.5%) as compared to the Total
Patient Group (27.2%: P-value = 0.031; OR = 1.4; 95%
CI: 1.0-2.0) and the TT Group (33.3%: P-value = 0.045;
OR = 1.9; 95% CI = 1.1-3.5). For the inhibitory genes, there
was a higher frequency of the homozygous KIR2DL2 re-
ceptor in the presence of C1 (KIR2DL2/2DL2-C1) in the
Total Patient Group when compared to the Control
Group (5.4% vs. 2.17%; P-value = 0.024; OR = 2.6; 95%
CI = 1.2-5.6) and higher frequencies for the TT (8.3% vs.
2.17%; P-value = 0.045; OR = 4.1; 95% CI = 1.3-12.6) and
LL (14.2% vs. 2.17%; P-value = 0.032; OR = 7.5; 95%
CI = 1.9-30.1) clinical forms compared to the Control
Group. In the analysis of the KIR2DL2/2DL3 haplotype
with its homozygous C1 ligand (KIR2DL2/2DL3 - C1/C1),
the frequency was lower in the Total Patient Group than
the Control Group (13.7% vs. 19.8%; P-value = 0.023;
OR = 0.6; 95% CI: 0.4-0.9).
We then investigated the influence of the number of
KIR-HLA class I pairs, inhibitory and activating, on the
development of leprosy and its clinical forms (Figure 1).
There were significant differences between the Total
Patient Group and Control Group (16.9% vs. 10.1%;
P-value = 0.006; OR = 1.8; 95% CI = 1.2-2.7) and between
the Borderline Group and the Control Group (17.8% vs.
10.1%; P-value < 0.001; OR = 2.3; 95% CI = 1.5-3.6) when
only one pair of inhibitory ligands was present. When
two pairs were present, there was a significance diffe-
rence between the TT and Control Groups (28.3% vs.
36.7%; P-value = 0.001; OR = 0.4; 95% CI = 0.2-0.8). In the
analysis of pairs of activating KIR-HLA class I ligands,
when just one pair was present, there was a statistically
significant difference between the TT and Control Groups
(46.6% vs. 32.6%; P-value = 0.047; OR = 1.8; 95% CI = 1.0-
3.1). When two pairs were present, there were statistically
significant differences between the TT and LL Groups
(20.0% vs. 0%; P-value = 0.024; OR = 11.0; 95% CI = 0.6-
19.8), and Borderline and LL Groups (17.2% vs. 0%:
P-value = 0.034; OR = 9.0; 95% CI = 0.5-15.1).
Additionally, multivariate logistic regression analysis
was performed using the stepwise method [13] to in-
vestigate relationships between epidemiological variables
(age, gender, and ethnic group) and genetic factors (KIR
genes) in the development of leprosy and its clinical
forms (Table 4). With respect to genetic factors, only
significant results from the Chi-square analysis were in-
cluded in the model. For gender, there was a significant
difference between the groups: LL vs. Control, TT vs.
Table 1 Distribution of the population of patients and healthy individuals according to clinical forms of leprosy, age,
gender and ethnic group
Per se LL Borderline TT Controls
N = 408 N = 21 N = 302 N = 60 N = 413
Age (Mean ± SD) 42.0 ± 16.4 45.7 ± 15.2 42.8 ± 15.9 37.4 ± 16.8 42.0 ± 14.5
(Median) 41 45 42 37 42
n (%) n (%) n (%) n (%) n (%)
Gender Male 250 (61.2) 17 (80.9) 194 (64.2) 25 (41.6) 249 (60.2)
Female 158 (38.7) 4 (19.0) 108 (35.7) 35 (58.3) 164 (37.7)
Ethnic Caucasian 146 (35.7) 8 (38.0) 115 (38.0) 14 (23.3) 137 (28.3)
Group Black 16 (3.92) 0 (0.0) 11 ( 3.64) 3 ( 5.0) 17 ( 4.11)
Afro-Brazilian 246 (60.2) 13 (61.9) 176 (58.2) 43 (71.6) 259 (62.7)
NOTE: Distribution of patients classified according to criteria of Ridley & Joplin: Leprosy (per se), Tuberculoid (TT), Borderline (BL, BB, BT), and Lepromatous (LL);
according to age, gender (male and female) and ethnicity (Caucasian, Black and Afro-Brazilian). Values in parentheses correspond to the percentages of each variable.
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Control, TT vs. Borderline and TT vs. LL. For the va-
riable ethnicity, there was only a significant difference
between the TT and Control and TT and Borderline
groups (Table 4). The KIR2DL1 gene was negatively as-
sociated in the comparisons between the groups: Total
Patient vs. Control (β = −2.2; OR = 0.1) LL vs. Control
(β = −2.8; OR = 0.06), TT vs. Control (β = −3.7; OR = 0.02)
and TT vs. Borderline (β = −1.8; OR = 0.1). In the presence
of the homozygous C2 ligand (KIR2DL1 - C2/C2) there
were positive associations between the groups: Total
Patient vs. Control (β = 0.4; OR = 1.5), TT vs. Control
(β = 1.6; OR = 5.0) and TT vs. Borderline (β = 1.9; OR = 6.9).
The difference in the frequency of the KIR2DL2-C1 gene
was significant for TT vs. Borderline and TT vs. Control
Groups. There were positive associations for KIR2DL2/
2DL2-C1 on comparing the LL and Control (β = 1.6;
OR = 5.0) and TT and Control Groups (β = 1.1; OR = 3.2)
and negative associations between the Borderline and LL
Groups (β = −1.5; OR = 0.2). The pair of KIR2DS2-C1 acti-
vating receptors was significant only between the Total
Patient and Control Groups (P-value = 0.002).
When only the HLA ligands of the KIR gene were
evaluated, they were in equilibrium of Hardy-Weinberg,
however no significant differences in their frequencies
were found between groups.
Discussion
Studying the impact of genes on infectious diseases such
as leprosy in endemic regions is extremely important be-
cause it provides information about the contributions of
host genetic factors and the environment in which the
individual lives on the development of the disease. His-
torically in Brazil, the Mid-Western region has always
had high rates of new cases of leprosy and the least
favourable evolution of endemics in Brazil [14]. A recent
study conducted by Magalhães et al. [15] assessed the
pattern of leprosy in the State of Mato Grosso. The data
revealed that the evolution of the disease was related to
the process by which the region was settled, with succes-
sive migrations causing changes in the epidemiological
structure due to the poor living conditions of the mi-
grant population associated with other factors of infec-
tion in the disease process.
The current study shows that men are more affected
by leprosy than women; the literature presents conflic-
ting results regarding the prevalence of leprosy with re-
spect to gender [16,17]. Some authors claim that the
greater social contact between men and their frequent
exposure to risk environments can contribute to the in-
creased number of cases [18]. Others claim that the
prevalence of the disease in men is not universal and
that, when related to leprosy reactions, women who are
pregnancy or breastfeeding are at greater risk due to
immunological and genetic characteristics [17]. In the
evaluation of ethnic background, the highest frequency
was found in Afro-Brazilians followed by Caucasians,
which reflects the greater proportion of half-castes in
the population of Mato Grosso.
The analysis of the distribution of the KIR genes high-
lights differences in the frequencies of activating genes
between the TT and LL forms of the disease, both separ-
ately and in the presence of the correlated HLA ligands.
Figure 2 compares these two clinical forms with respect to
activating genes and their ligands; there is a higher fre-
quency of all KIR-HLA combinations in the TT compared
to the LL form except for the KIR2DS2-C1/C1 combi-
nation, thus supporting the results found by Franceschi
et al. [10]. The results for activating genes (Table 2)
are also in accordance with the results described by
Franceschi et al. [10], who reported a higher frequency of
the KIR2DS1, 2DS2, 2DS3 and 2DS4 genes in TT
compared to LL patients. The initial step in eliminating
M. leprae requires the effective participation of the innate
immune system, and thus NK cells play an important role.
The activation of NK cells results in the production of
IFN-γ, the main cytokine involved in the activation of
macrophages, which promote the death of phagocytosed
mycobacteria. Furthermore, the stimulation of macro-
phages by IFN-γ results in the production of TNF, which
along with IFN-γ contributes to the activity of these cells
Table 2 Distribution of the frequencies of KIR genes in
patients with leprosy and their clinical forms and healthy
individuals in the population of Rondonopolis, MT
Genes Per se LL Borderline TT Controls
N = 408 N = 21 N = 302 N = 60 N = 413
n (%) n (%) n (%) n (%) n (%)
KIR2DL1 355 (87.0)a 19 (90.4) 260 (86.0)a 56 (93.3) 397 (96.2)a
KIR2DL2 290 (72.0) 14 (66.6) 209 (69.2) 48 (80.0) 300 (72.6)
KIR2DL3 363 (88.9) 18 (85.7) 272 (90.0) 53 (88.3) 380 (92.0)
KIR2DL4 405 (99.2) 21 (100) 300 (99.3) 60 (100) 409 (99.0)
KIR2DL5 227 (55.6) 8 (38.0) 167 (55.2) 36 (60.0) 225 (54.4)
KIR3DL1 388 (95.0) 21 (100) 286 (94.7) 58 (96.6) 392 (94.9)
KIR3DL2 405 (99.2) 21 (100) 301 (99.6) 59 (98.3) 413 (100)
KIR3DL3 406 (99.5) 21 (100) 301 (99.6) 60 (100) 413 (100)
KIR2DS1 151 (37.0) 5 (23.8) 112 (37.0) 25 (41.6) 156 (37.7)
KIR2DS2 215 (52.6) 10 (47.6) 159 (52.6) 30 (50.0) 197 (47.6)
KIR2DS3 123 (30.1) 4 (19.0) 90 (29.8) 19 (31.6) 129 (60.5)
KIR2DS4 387 (94.8) 21 (100) 286 (94.7) 57 (95.0) 386 (93.4)
KIR2DS5 144 (35.2) 5 (23.8) 107 (35.4) 23 (38.3) 157 (38.0)
KIR3DS1 148 (36.2) 4 (19.0)b 107 (35.4) 26 (43.3)b 153 (37.0)
NOTE: Data represent the number of KIR genes and values in parentheses
correspond to the percentages of each gene. TT: Tuberculoid, Borderline (BL,
BB, BT), LL: Lepromatous.
aKIR2DL1: P < 0.001, Pc < 0.014, OR = 0.26 (0.15 – 0.48) to per se vs. controls
P < 0.001, Pc < 0.014, OR = 0.24 (0.13 – 0.45) to Borderline vs. controls.
bKIR3DS1: P = 0.07 (tendency) to TT vs. LL.
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against mycobacteria [19]. The higher frequency of acti-
vating genes in the group of TT patients compared to the
LL group may enable a more efficient activation of NK
cells, resulting in a low bacillary load and fewer skin and
nerve lesions, i.e., a milder disease, thereby protecting pa-
tients against the most severe form of the disease.
In the analysis of activating KIR genes, the KIR2DS2-
C1 pair was significantly more common in the Total
Patient and TT Groups than the Control Group. It is
important to note the presence of a strong binding
imbalance between the KIR2DL2 and KIR2DS2 genes
[9], as was confirmed in this study. The KIR2DL2/2DS2
haplotype frequencies were higher than expected in
the Total Patient and Control Groups. Considering
the presence of linkage disequilibrium between these
two genes, the presence of the association may be
attributable to the high frequency of the KIR2DL2 gene
for both Groups.
The function of the KIR genes in the immune response
is highly dependent on the HLA molecules expressed on
the surface of target cells; the KIR-HLA interaction can
result in either activation or inhibition of NK cells. The
recognition of specific HLA molecules by inhibiting KIRs
is well established [20], with a hierarchy of inhibition of
the KIR2DL molecules: 2DL1-C2/C2 has the greatest in-
hibitory potential, followed by 2DL2-C1 and 2DL3-C1
[21]. In this study, was found a tendency of association for
the gene KIR2DL1-C2C2 between the BL and BT forms,
which are two opposite clinical forms, being BL nearer to
the lepromatous pole. The results suggest that greater in-
hibition of NK cells may occur in these patients, leading
to a more severe manifestation of the disease.
Table 3 Frequencies of KIR genes in the presence of their ligands HLA Class I in patients with leprosy and their clinical
forms and healthy individuals in the population of Rondonópolis, MT
KIR – HLA Class I Per se LL Borderline TT Controls
N = 408 N = 21 N = 302 N = 60 N = 413
n (%) n (%) n (%) n (%) n (%)
KIR2DL1 – C2 173 (42.4) 10 (47.6) 121 (40.0) 29 (48.3) 188 (45.5)
KIR2DL1 – C2/C2 82 (20.0) 5 (23.8) 59 (19.5) 14 (23.3) 79 (19.1)
KIR2DL2 – C1 145 (35.5) 8 (38.0) 95 (31.4) 27 (45.0) 134 (32.4)
KIR2DL2 – C1/C1 71 (17.4) 2 (9.52) 56 (18.5) 11 (18.3) 95 (23.0)
KIR2DL3 – C1 174 (42.6) 9 (42.8) 128 (42.3) 26 (43.3) 184 (44.5)
KIR2DL3 – C1/C1 92 (22.5) 3 (14.2) 71 (23.5) 13 (21.6) 116 (28.0)
KIR3DL1 – Bw4 153 (37.5) 7 (33.3) 118 (39.0) 18 (30.0) 164 (39.7)
KIR3DL1 – Bw4/Bw4 44 (10.7) 2 (9.52) 33 (10.9) 7 (11.6) 54 (13.0)
KIR3DL2 – A*03/*11 99 (24.2) 4 (19.0) 74 (24.5) 15 (25.0) 86 (20.8)
KIR2DS1 – C2 70 (17.1) 2 (9.52) 48 (15.8) 14 (23.3) 74 (17.9)
KIR2DS1 – C2/C2 38 (9.31) 2 (9.52) 27 (8.94) 7 (11.6) 25 (6.05)
KIR2DS2 – C1 111 (27.2)a 5 (23.8) 74 (24.5) 20 (33.3)a 85 (20.5)a
KIR2DS2 – C1/C1 51 (12.5) 3 (14.2) 39 (12.9) 6 (10.0) 60 (14.5)
KIR3DS1 – Bw4 57 (13.9) 1 (4.76) 46 (15.2) 7 (11.6) 59 (14.2)
KIR3DS1 – Bw4/Bw4 21 (5.14) 1 (4.76) 16 (5.29) 4 (6.66) 23 (5.56)
KIR2DL2/2DL2 – C1 22 (5.39)b 3 (14.2)b 10 (3.31)b 5 (8.33)b 9 (2.17)b
KIR2DL2/2DL2 – C1/C1 14 (3.43) 0 (0.0) 11 (3.64) 2 (3.33) 10 (2.42)
KIR2DL2/2DL3 – C1 122 (29.9) 6 (28.5) 88 (29.1) 19 (31.6) 124 (30.0)
KIR2DL2/2DL3 – C1/C1 56 (13.7)c 2 (9.52) 43 (14.2) 11 (18.3) 82 (19.8)c
KIR2DL3/2DL3 – C1 55 (13.4) 4 (19.0) 44 (14.5) 5 (8.33) 62 (15.0)
KIR2DL3/2DL3 – C1/C1 34 (8.33) 1 (4.76) 25 (8.27) 4 (6.66) 32 (7.74)
NOTA: Data represent the number of KIR genes and their respective ligands HLA Class I; the values in parentheses correspond to the percentages of each
pair KIR-HLA.
TT: Tuberculoid, Borderline (BL, BB, BT), LL: Lepromatous.
aKIR2DS2 – C1: P = 0.031, OR = 1.4 (1.0 – 2.0) to per se vs. controls; P = 0.045, OR = 1.9 (1.1 – 3.5) to TT vs. controls.
bKIR2DL2/2DL2 – C1: P = 0.024, OR = 2.6 (1.2 – 5.6) to per se vs. controls; P = 0.045, OR = 4.1 (1.3 – 12.6) to TT vs. controls; P = 0.032, OR = 7.5 (1.9 – 30.1) to LL vs.
controls; P = 0.057 (tendency) to Borderline vs. LL.
cKIR2DL2/2DL3 – C1/C1: P = 0.023, OR = 0.6 (0.4 – 0.9) to per se vs. controls.
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The distribution of the KIR2DL3 and KIR2DL2 inhi-
bitory genes, and whether they were homozygous or
heterozygous, was observed in this study, supporting the
hypothesis that these genes segregate as alleles from a
single locus [21,22]. Interesting results were found for
KIR2DL2/2DL2-C1; its frequency was higher in all patient
groups compared to the Control Group, although the
difference was only significant for the Total Patient, TT
and LL Groups, suggesting that the inhibitory effect of
KIR2DL2/2DL2-C1 may contribute to the development of
Table 4 Stepwise logistic regression analysis of factors associated with the development of leprosy and its clinical
forms
Variable response Variable independent Coefficient (β) P OR −2Log
per se vs. controls KIR2DL1 −2.227 0.001 0.10 1060.2
KIR2DL1 - C2/C2 0.431 0.022 1.54
KIR2DS2 - C1 0.537 0.002 1.71
LL vs. controls Gender −1.217 0.047 0.29 141.9
KIR2DL1 −2.815 0.001 0.06
KIR2DL2/2DL2 - C1 1.612 0.042 5.01
Borderline vs. controls KIR2DL1 −1.868 0.001 0.15 936.9
TT vs. controls Gender 0.755 0.017 2.13 288.5
Ethnic 0.365 0.048 1.44
KIR2DL1e −3.708 0.001 0.02
KIR2DL1 - C2/C2 1.612 0.001 5.01
KIR2DL2 - C1 1.452 0.001 4.27
KIR2DL2/2DL2 - C1 1.173 0.059 3.23
TT vs. Borderline Gendera 0.947 0.002 2.57 281.7
Ethnic 0.410 0.017 1.50
KIR2DL1 −1.809 0.001 0.16
KIR2DL1 - C2/C2 1.932 0.001 6.90
KIR2DL2 - C1 1.840 0.001 6.30
TT vs. LL Gender 1.783 0.004 5.95 82.4
Borderline vs. LL KIR2DL2/2DL2 - C1 −1.579 0.024 0.206 151.3
NOTE: To this analysis, only KIR genes that were significant in the chi-square analysis were considered. (β): Coefficient of variables; −2Log: Logarithm of chance.
Tuberculoid (TT), Borderline (BL, BB, BT), and Lepromatous (LL).
Figure 1 Frequencies of pairs of ligands KIR-HLA Class I inhibitory and activating in leprosy patients and their clinical forms and
healthy individuals in the population of Rondonopolis, MT. NOTE: Bars diagram depicting the frequency of pairs of KIR-HLA inhibitory and
activacting. TT: Tuberculoid, Borderline (BL, BB, BT), LL: Lepromatous. *Represents that the LL group presented results of 0% for two activacting
pairs. aTo one inhibitory pair: P = 0.006, OR = 1.8 (1.2 – 2.7) to per se vs. controls and P < 0.001, OR = 2.3 (1.5 – 3.6); to Borderline vs. controls. bTo
two inhibitory pairs: P = 0.001, OR = 0.4 (0.2 – 0.8) to TT vs. controls. cTo one activating pair: P = 0.047, OR = 1.8 (1.0 – 3.1) to TT vs. controls. dTo
two activating pairs: P = 0.024, OR = 11.0 (0.6 – 19.8) to TT vs. LL and P = 0.034, OR = 9.0 (0.5 – 15.1) to Borderline vs. LL.
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leprosy, but mainly contributes to a worse prognosis in
M. leprae infections.
It is important to highlight the results observed in the
analysis of the number of pairs of KIR-HLA ligands. The
Total Patient Group had a more inhibitory profile due to
the higher frequency of only one inhibitory pair than the
Control Group, which may favour the development of
the disease. A similar result was found for the Borderline
Group of patients compared to the Control Group.
Interestingly, in the analysis of the activating pairs of
ligands, a higher frequency of two pairs was observed in
the borderline patients compared to the LL Group. The
interpolar forms, termed borderline, comprised the ma-
jority of the cases. The analysis of the KIR-HLA ligand
pairs in this group showed a more inhibitory profile rela-
tive to the Control Group, added to a more activating
profile compared to the LL Group. These individuals
have a characteristic immune instability against the
mycobacteria, which means that there is great variation
in their clinical manifestations, whether of the skin,
nerves, or systemic involvement. The balance between
activation and inhibition of NK cells may explain the ill-
defined characteristics observed in these patients.
The results of the multivariate analysis, in addition to
confirming the influence of the KIR genes and their
HLA ligands on the immunopathology of leprosy and its
different forms, demonstrated the influence of gender.
Interestingly, the LL Group presented a negative asso-
ciation with respect to gender compared to the Control
Group. Thus, there were fewer females in the LL Group
compared to the Control Group. On the other hand,
there was a positive association with respect to gender
on comparing the TT Group: TT vs. Control (β = 0.7;
OR = 2.1), TT vs. Borderline (β = 0.9; OR = 2.5) or TT vs.
LL (β = 1.7; OR = 5.9). Among the groups, the TT Group
was the only one that comprised more women than
men. These results suggest that being a woman is a pro-
tective factor against the most severe form and spread of
the disease, in addition to contributing to its mildest
manifestation with susceptibility to the TT form. Specific
immune responses to autoimmune and infectious diseases
differ between men and women. The female sex hormone,
oestrogen, can increase the production of INF-γ and IL-2,
thereby influencing the immune response in women.
Gonadotropin-releasing hormone (GnRH) is involved in
the maturation of the thymus and exerts a potent stimula-
tory effect, leading to increases in IL-2 and its receptor
(IL-2R), INF-γ and activation of CD4+ helper T cells [23].
The male androgens, on the other hand, are related to the
inhibition of T and B cell immune response and are found
at low levels in men suffering from autoimmune diseases
such as systemic lupus erythematosus [24].
With respect to ethnicity, the multivariate analysis dem-
onstrated a positive association between TT and controls
(β 0.3; OR 1.4) and between TT and Borderline (β 0.4; OR
1.5). For both groups, the TT Group had a higher fre-
quency of Afro-Brazilians. It is possible that the migra-
tions that occurred during settlement of the State of Mato
Grosso influenced the ethnic composition of the po-
pulation, whereby individuals classified as of mixed des-
cent result from miscegenation between Afro-Brazilians
and Indians.
The significant difference in the percentage of the
KIR2DL1 gene in the Total Patient and Borderline Groups
compared to the Control Group in the Chi-square analysis
was also significant in some multivariate analysis compari-
sons; however, in both cases the results were not corre-
lated with the development of the disease or its different
forms. KIR2DL1-C2/C2, which was not significant in the
Chi-square analysis, was significantly different in the
Figure 2 Distribution of the frequencies of KIR genes activating in the presence of their ligands HLA Class I in patients with the clinical
forms Tuberculoid and Lepromatous in the population of Rondonopolis, MT. NOTE: Bars diagram depicting the frequency of KIR genes
activacing genes and their respective ligands HLA Class I in patients with the Tuberculoid and Lepromatous clinical forms; the values in parentheses
correspond to the percentages of each pair KIR-HLA. TT: Tuberculoid; LL: Lepromatous.
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comparison between the Total Patient and Control groups;
however, this did not result in associations with the disease
or its clinical forms. The KIR2DL2/2DL2-C1 inhibitory
pair, which was significant in the Chi-square analysis, was
also significant in the multivariate analysis (LL vs. Control;
Borderline vs. LL), with a tendency being seen in the com-
parison between the TT vs. Control Groups. The signifi-
cance of KIR2DL2-C1 in the multivariate analysis may be
due to the higher frequency of this pair in the TT Group
(45.0%), but without implications for the pathogenesis
of the disease. An equivalent result was observed for
KIR2DS2-C1, whose significance, found when comparing
the Total Patient and Control Groups, is probably due to a
linking imbalance with KIR2DL2 as reported for the two
groups in this study.
Conclusion
The current study shows that activating and inhibitory KIR
genes in the presence of their corresponding HLA ligands
may have some effect on the development of leprosy and
its clinical forms, seen particularly with the strong presence
of activating genes in the TT Group. The balance between
activating and inhibitory genes may interfere with the pro-
gression of the disease to milder or more aggressive forms,
or even cause it to vary between the two poles with inde-
terminate forms, thus highlighting the role of NK cells in
the immunopathology of the disease.
The highlight of this study was identifying the profiles
of patients with leprosy from a hyperendemic area of the
country and comparing them to a group of extremely
well matched healthy individuals.
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